• Je něco špatně v tomto záznamu ?

Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders

J. Mihályová, K. Hradská, T. Jelínek, B. Motais, P. Celichowski, R. Hájek

. 2021 ; 22 (21) : . [pub] 20211025

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003421

Grantová podpora
FV40145 This work was supported by the the project no. FV40145 Genetically modified donor T cells as a universal cell source for the immunotherapy of tumors using T lymphocytes equipped with a chimeric antigen receptor (CAR)

Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T (CAR-T) cell therapy, commonly use B-cell-associated antigens (CD19, CD20, CD22, and CD79b) as one of their targets. T-cell engagers (TCEs), a subclass of bsAbs, work on a similar mechanism as CAR-T cell therapy without the need of previous T-cell manipulation. Currently, several anti-CD20xCD3 TCEs have demonstrated promising efficacy across different lymphoma subtypes with slightly better outcomes in the indolent subset. Anti-CD19xCD3 TCEs are being developed as well but only blinatumomab has been evaluated in clinical trials yet. The results are not so impressive as those with anti-CD19 CAR-T cell therapy. Antibody-drug conjugates targeting different B-cell antigens (CD30, CD79b, CD19) seem to be effective in combination with mAbs, standard chemoimmunotherapy, or immune checkpoint inhibitors. Further investigation will show whether immunotherapy alone or in combinatory regimens has potential to replace chemotherapeutic agents from the first line treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003421
003      
CZ-PrNML
005      
20220127150242.0
007      
ta
008      
220113s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms222111470 $2 doi
035    __
$a (PubMed)34768899
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mihályová, Jana $u Department of Haematooncology, University Hospital Ostrava, 708 52 Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, 708 52 Ostrava, Czech Republic
245    10
$a Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders / $c J. Mihályová, K. Hradská, T. Jelínek, B. Motais, P. Celichowski, R. Hájek
520    9_
$a Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T (CAR-T) cell therapy, commonly use B-cell-associated antigens (CD19, CD20, CD22, and CD79b) as one of their targets. T-cell engagers (TCEs), a subclass of bsAbs, work on a similar mechanism as CAR-T cell therapy without the need of previous T-cell manipulation. Currently, several anti-CD20xCD3 TCEs have demonstrated promising efficacy across different lymphoma subtypes with slightly better outcomes in the indolent subset. Anti-CD19xCD3 TCEs are being developed as well but only blinatumomab has been evaluated in clinical trials yet. The results are not so impressive as those with anti-CD19 CAR-T cell therapy. Antibody-drug conjugates targeting different B-cell antigens (CD30, CD79b, CD19) seem to be effective in combination with mAbs, standard chemoimmunotherapy, or immune checkpoint inhibitors. Further investigation will show whether immunotherapy alone or in combinatory regimens has potential to replace chemotherapeutic agents from the first line treatment.
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a lidé $7 D006801
650    _2
$a imunokonjugáty $x terapeutické užití $7 D018796
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a B-buněčný lymfom $x farmakoterapie $x imunologie $x patologie $7 D016393
650    _2
$a lymfoproliferativní nemoci $x farmakoterapie $x imunologie $x patologie $7 D008232
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hradská, Katarína $u Department of Haematooncology, University Hospital Ostrava, 708 52 Ostrava, Czech Republic
700    1_
$a Jelínek, Tomáš $u Department of Haematooncology, University Hospital Ostrava, 708 52 Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, 708 52 Ostrava, Czech Republic
700    1_
$a Motais, Benjamin $u Faculty of Medicine, University of Ostrava, 708 52 Ostrava, Czech Republic
700    1_
$a Celichowski, Piotr $u Faculty of Medicine, University of Ostrava, 708 52 Ostrava, Czech Republic
700    1_
$a Hájek, Roman $u Department of Haematooncology, University Hospital Ostrava, 708 52 Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, 708 52 Ostrava, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 21 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34768899 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150238 $b ABA008
999    __
$a ok $b bmc $g 1751010 $s 1154570
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 21 $e 20211025 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a FV40145 $p This work was supported by the the project no. FV40145 Genetically modified donor T cells as a universal cell source for the immunotherapy of tumors using T lymphocytes equipped with a chimeric antigen receptor (CAR)
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace